About

Glycanostics® has developed an early-stage, highly accurate and unique cancer diagnostic test that analyses changes in glycan structures in glycoprotein biomarkers from blood serum. Giasay® Prostate cancer test is being launched in Europe in Q2 2023, to be followed by Giasay®breast cancer test at the end of 2023. Our PCT patent also covers lung cancer, pancreatic cancer, ovarian, testicular, bladder, stomach, liver, colorectal and thyroid cancer. Giasay® test has the following unique features: - It is minimally invasive (it analyses glycans from blood serum), - It detects early stage of the disease with high accuracy, - It is fast and easy to work with, - Affordable, - It reduces the number of false-positive results significantly, - It is compatible with equipment already used by laboratories world-wide (ELISA), - It also provides solutions for large-scale screening, - It is organ specific, and - Suitable for disease monitoring. About GLYCANOSTICS Glycanostics® is a biotech company with a vision to “Create a world, where cancer will be diagnosed early and treated successfully”. Key facts: - In October 2024 we became members of the highly prestigious EIC Scaling Club that unites 120 European deep-tech scale-ups with unicorn potential; - Our aim is to develop highly accurate, early-stage tests for the detection of 11 types of cancer based on analysis of glycans in blood serum; - Our patented technology enables to analyse glycans using Magnetic-based-ELISA; - Our solution represents a novel and unique approach, suitable for massive testing in laboratory chains, it detects cancer in early stage, with accuracy exceeding competitors, it is highly affordable and organ specific; - We are working hard to complete the CE mark registration process of our first product, Giasay® Prostate cancer test, which we anticipate in Q2 2026. Commercial launch is planned in Europe in 2026, to be followed by Giasay® Breast cancer test in 2027. Glycanostics is now looking for a strategic partner to discuss: - exclusive, world-wide licence to promote, sell and distribute its tests; - strategic collaboration for developing tests for further cancer types; - participation in Series A investment round. We are seeking €10M that can be split between the private investor(s) and EIC Fund, who will match the conditions of the lead investor.